Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

37 results
Display

Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after BreastConserving Surgery

Cheun JH, Won J, Jung JG, Kim HK, Han W, Lee HB

Purpose: Trastuzumab is effective in early and advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, few studies have reported the effect of trastuzumab on ipsilateral breast tumor...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
MicroRNA-130a Increases and Predicts Cardiotoxicity during Adjuvant Chemotherapy in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

Feng Q, Ren Y, Hou A, Guo J, Mao Z, Liu S, Wang B, Bai Z, Hou X

Purpose: This study aimed to investigate the changes in microRNA-130a (miR-130a) and its correlation with cardiotoxicity during epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab (EC-D+T) adjuvant chemotherapy in human epidermal growth...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2–Targeted Agent in the Real-World Setting

Koo DH, Ryu MH, Lee MY, Chae H, Kim EJ, Moon MS, Kang YK

Purpose This study aimed to evaluate the survivals of patients with metastatic or recurrent gastric cancer (MRGC) over a period of 16 years and to investigate the recent changes in chemotherapy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cutaneous Photosensitivity Possibly Induced by Paclitaxel and Trastuzumab

Lee HY, Jeon YJ, Koo DW, Lee JS

  • KMID: 2512424
  • Korean J Dermatol.
  • 2021 Jan;59(1):77-79.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Updated Bayesian Network MetaAnalysis of Adjuvant Targeted Treatment Regimens for Early Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer

Li X, Yao L, Wang M, Wang M, Li X, Yu X, Guo J, Dong H, Sun X, Xu Y

Purpose: Combining targeted agents with adjuvant chemotherapy prolongs survival in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, but also increases the risk of adverse effects. The updated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Radioisotope-ADME studies of Trastuzumab-monomethyl auristatin F in tumor bearing mice and healthy marmosets

Lee HW, Jeong YH, Hwang JA, Lee JJ, Yu AR, Kang JA, Raza MA, Park SH, Park YH, Kim DH

Radioisotope ADME (RI-ADME) studies are enabling visualization of the biodistribution in molecular imaging. We applied RI-ADME to investigate the tumor targeting capacity and biodistribution of trastuzumab-monomethyl auristatin F (LCB14-0110) in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients

Schneider J, Lee HJ, Nam SJ, Lee SJ, Jung JH, Jung SH, Lim ST, Jeon YW, Gwak H

Purpose: Neoadjuvant chemotherapy (NAC) involving trastuzumab markedly increases pathologic complete response (pCR) rates in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Despite increasing pCR rates, long-term...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of survival outcomes according of patients with metastatic gastric cancer receiving trastuzumab with systemic chemotherapy

Ha GY, Yang SH, Kang HJ, Lee HL, Kim J, Kim YJ, Yu HJ, Lee JI, Jin SH

Purpose: Currently, trastuzumab plus chemotherapy is the standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic gastric cancer (mGC) or esophagogastric junction cancer. However, it...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data

Kim EK, Cho J, Kim JY, Chang SA, Park SJ, Choi JO, Lee SC, Ahn JS, Park SW, Im YH, Jeon ES, Park YH

PURPOSE: While concerns regarding trastuzumab-related cardiac dysfunction (TRCD) in patients with breast cancer are increasing, there is a lack of evidence supporting the current recommendations for TRCD monitoring. We aimed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Central Nervous System Failure in Korean Breast Cancer Patients with HER2-Enriched Subtype: Korean Radiation Oncology Group 16-15 Multicenter Retrospective Study

Kim K, Shin KH, Kim JH, Choi DH, Park W, Kim YB, Kim HJ, Kim JH, Park H, Lee SY, Kim J, Oh DH, Kim IA

PURPOSE: The purpose of this study was to evaluate the risk of central nervous system (CNS) failure in Korean patients with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection

Prieto M, Gastaca M, Ruiz P, Ventoso A, Palomares , Perfecto A, Valdivieso A

Surgery is the only treatment for biliary tract cancer with long term survival. Unfortunately, most patients are diagnosed at stage IV with distant metastases. In these circumstances, life expectancy is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy

Kim SB, Do IG, Tsang J, Kim TY, Yap YS, Cornelio G, Gong G, Paik S, Lee S, Ng TY, Park S, Oh HS, Chiu J, Sohn J, Lee M, Choi YJ, Lee EM, Park KH, Nathaniel , Ro J

PURPOSE: BioPATH is a non-interventional study evaluating the relationship of molecular biomarkers (PTEN deletion/downregulation, PIK3CA mutation, truncated HER2 receptor [p95HER2], and tumor HER2 mRNA levels) to treatment responses in Asian...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment

Chae H, Yoo C, Yoon JA, Lee HJ, Kim KP, Kim JE, Ahn JH, Jung KH, Gong G, Kim SB

PURPOSE: The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has markedly improved since the introduction of trastuzumab. We aimed to evaluate the association between stromal tumor-infiltrating...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer

El-Enbaby , El Moneim , El atti Khedr GA, Elwany YM

PURPOSE: This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data

You SH, Chae BJ, Eom YH, Yoo TK, Kim YS, Kim JS, Park WC

PURPOSE: Triple-positive breast cancer is defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) positivity. Several systemic breast cancer therapies target hormonal and HER2 responsiveness....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab

Kim IH, Lee JE, Youn HJ, Song BJ, Chae BJ

PURPOSE: We intended to determine whether dexrazoxane (DZR) is cardioprotective during administration of adjuvant anthracycline-based chemotherapy followed by a 1-year trastuzumab treatment. METHODS: The medical records of 228 patients who underwent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trastuzumab Exposure during Pregnancy with Invasive Breast Cancer

Min JW, Kang YD

Trastuzumab is a monoclonal antibody used for the treatment of human epidermal growth factor receptor-2 positive breast cancer. There is a little information in the literature regarding the safe use...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trastuzumab-associated autoimmune thyroid disease in a patient with metastatic breast cancer

Min HK, Kim IH, Kim JY, Ban TH, Kim KH, Ha J, Kim JH

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis

Park WY, Kim HJ, Kim K, Bae SB, Lee N, Lee KT, Won JH, Park HS, Lee SC

Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology

Yi JH, Kang JH, Hwang IG, Ahn HK, Baek HJ, Lee SI, Lim DH, Won YW, Ji JH, Kim HS, Rha SY, Oh SY, Lee KE, Lim T, Maeng CH, Kim MJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH

PURPOSE: While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr